Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

1.61
-0.0100-0.62%
Post-market: 1.60-0.0100-0.62%19:57 EDT
Volume:435.09K
Turnover:707.13K
Market Cap:77.78M
PE:-1.10
High:1.67
Open:1.64
Low:1.60
Close:1.62
Loading ...

Cassava Sciences Shares Fall 4% After 84% Slump in Previous Session

THOMSON REUTERS
·
26 Nov 2024

Stock Track | Cassava Sciences Stock Plunges 5.47% on Analyst Downgrade

Stock Track
·
26 Nov 2024

Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)

Zacks
·
26 Nov 2024

HC Wainwright Downgrades Cassava Sciences to Neutral From Buy

MT Newswires Live
·
26 Nov 2024

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Cassava Sciences to Advance, MicroStrategy to Decline

MT Newswires Live
·
26 Nov 2024

Cassava Sciences downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
26 Nov 2024

Cassava Sciences, Inc. : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
26 Nov 2024

Stock Track | Cassava Sciences Inc. (SAVA) Soars 8.5% in Pre-Market Amid Rebound From Massive Plunge

Stock Track
·
26 Nov 2024

Stock Track | Cassava Sciences Inc (SAVA) Soars 5.24% as Stock Rebounds After Massive Plunge on Failed Alzheimer's Drug Trial

Stock Track
·
26 Nov 2024

24H|Super Micro Drops 3%; Zoom Sinks 6%; Cassava Sciences Rebounds 3% After Plunging 84%

Tiger Newspress
·
26 Nov 2024

Post-Bell|Wall St Closes Higher; Small-Caps Hit Record High; SMCI Surges 16%; Nvidia, Tesla Fall 4%

Tiger Newspress
·
26 Nov 2024

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

MT Newswires Live
·
26 Nov 2024

Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals

Dow Jones
·
25 Nov 2024

Cassava Sciences Stock Slides 84% as Alzheimer's Trial Fails -- Barrons.com

Dow Jones
·
25 Nov 2024

Cassava Sciences Shares Plunge 85% After Co's Alzheimer's Drug Fails in Late-Stage Study

THOMSON REUTERS
·
25 Nov 2024

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Benzinga
·
25 Nov 2024

Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study

Investopedia
·
25 Nov 2024

D. Boral says Anavex Alzheimer’s approach superior to Cassava

TIPRANKS
·
25 Nov 2024

JonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)

TIPRANKS
·
25 Nov 2024

Morning Brew: Cassava Sciences Plummets on Alzheimer's Trial Results

GuruFocus
·
25 Nov 2024